Triple Helix Discovery Engine
Award Announcements & Progress Reports: Federal Contracts, Grants & Cooperative Agreements
*SBIR-Small Business Innovative Research (Awards)
SBIR:Awardees By Agency
SBIR (Small Business Innovation Research) Program-DOD Awardees

Impel Neurpharma

Parents

*Architects: Biodefense (CBRNE), WMD, Disaster Preparedness, Emergency Response & Relief, Pandemic Resilience
*Architects: Drug Delivery (Inhalation, Nasal, Powder)
*Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies (Pharmaceuticals, Drugs, Biotechnology, Biosimilars)
NIH: R&D Awardees
SBIR (Small Business Innovation Research) Program-DOD Awardees

As a result, a lower drug dosage may be utilized, thereby lowering plasma exposure and potentially reducing systemic side effects.
Impel is developing a novel drug delivery device to enable central nervous system drugs to bypass the blood-brain barrier, Impel NeuroPharma
Impel NeuroPharma Awarded Phase II SBIR by Department of Defense for Blood-Brain Barrier Bypass Technology(2011)
Impel Snags $750K Grant (2011)
Impel’s Pressurized Olfactory Delivery (POD) device delivers drugs to the upper nasal cavity where they are directly transported into the brain, effectively bypassing the blood-brain barrier (BBB).
Method for Delivering Drugs through the Upper Nasal Cavity, Bypassing the Blood-brain Barrier, Which Limits the Effectiveness of Many Neurological Drugs
Received a Phase II Small Business Investigational Research (SBIR) grant from the Department of Defense’s Chemical and Biological Defense SBIR Program entitled, “Blood Brain Barrier Drug Delivery of Therapeutics for Chemical Warfare Agents.”
Seattle, Washington
The POD device is compatible with liquid and powder formulations of both small molecule and biologic drugs.
The POD device is designed to enable molecules to become therapeutics that were previously unable to cross the BBB.